Callan Capital’s Novo Nordisk NVO Stock Holding History

Callan Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$1.54M	Sell	22,223 -3,096	-12%	-$256K	0.11%	87
2024 Q4	$2.18M	Sell	25,319 -1,097	-4%	-$119K	0.16%	70
2024 Q3	$3.15M	Buy	26,416 +1,719	+7%	+$229K	0.22%	63
2024 Q2	$3.53M	Buy	24,697 +1,155	+5%	+$153K	0.29%	57
2024 Q1	$3.02M	Buy	23,542 +2,283	+11%	+$272K	0.27%	55
2023 Q4	$2.2M	Buy	21,259 +15,366	+261%	+$1.52M	0.21%	57
2023 Q3	$536K	Buy	5,893 +1,649	+39%	+$145K	0.06%	118
2023 Q2	$343K	Hold	4,244	–	–	0.04%	134
2023 Q1	$338K	Hold	4,244	–	–	0.04%	135
2022 Q4	$287K	Buy	4,244 +200	+5%	+$11.7K	0.04%	149
2022 Q3	$201K	Hold	4,044	–	–	0.03%	127
2022 Q2	$225K	Sell	4,044 -92	-2%	-$5.11K	0.03%	107
2022 Q1	$230K	Hold	4,136	–	–	0.03%	113
2021 Q4	$232K	Buy	+4,136	New	+$224K	0.03%	125

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

TIM

Thornburg Investment Management Santa Fe, New Mexico $9.63B AUM 35.65% 1-Year Est. Return

Callan Capital's NVO Position: Q1 2025 in Review

Callan Capital reduced its Novo Nordisk (NVO) stake by 12% in Q1 2025, selling an estimated $256K and leaving 22,223 shares worth $1.54M. The position accounts for 0.11% of the portfolio, ranked #87.

Callan Capital first reported a position in NVO in Q4 2021 and has held it in 14 quarters since. The position peaked at $3.53M in Q2 2024. 1,528 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

Callan Capital held 22,223 shares of Novo Nordisk worth $1.54M as of Q1 2025.
Callan Capital sold 3,096 Novo Nordisk shares in Q1 2025, an estimated $256K.
Novo Nordisk made up 0.11% of Callan Capital's portfolio in Q1 2025, its #87 holding.
Callan Capital first reported a position in Novo Nordisk in Q4 2021 and has held it in 14 quarters since.
Callan Capital's Novo Nordisk position peaked at $3.53M in Q2 2024.
1,528 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on Callan Capital's 13F filing for Q1 2025, filed 29 Apr 2025.